{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:14:29Z","timestamp":1792620869228,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PK) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA). This prospective clinical PK study was conducted at King Chulalongkorn Memorial Hospital between July 2019 to April 2021, evaluating seven acute liver failure (ALF) and seven acute-on-chronic liver failure (ACLF) patients who received CRRT support utilizing RCA as an anticoagulant at a citrate dose of 3\u00a0mmol\/L. For evaluation of the citrate PK, we delivered citrate for 120\u00a0min and then stopped for a further 120\u00a0min. Total body clearance of citrate was 152.5\u2009\u00b1\u200950.9 and 195.6\u2009\u00b1\u2009174.3\u00a0mL\/min in ALF and ACLF, respectively. The ionized calcium, ionized magnesium, and pH slightly decreased after starting citrate infusion and gradually increased to baseline after stopping citrate infusion. Two of the ACLF patients displayed citrate toxicity during citrate infusion, while, no ALF patient had citrate toxicity. In summary, citrate clearance was significantly decreased in critically ill ALF and ACLF patients receiving CRRT. Citrate use as an anticoagulation in these patients is of concern for the risk of citrate toxicity.<\/jats:p>","DOI":"10.1038\/s41598-022-05867-8","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T11:06:03Z","timestamp":1643799963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT"],"prefix":"10.1038","volume":"12","author":[{"given":"Peerapat","family":"Thanapongsatorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weerachai","family":"Chaijamorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatadon","family":"Sirivongrangson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasipha","family":"Tachaboon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadudee","family":"Peerapornratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttha","family":"Lumlertgul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroonrut","family":"Lucksiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattachai","family":"Srisawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"issue":"1","key":"5867_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"JA Kellum","year":"2012","unstructured":"Kellum, J. A. et al. Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group: KDIGO clinical practice guideline for acute kidney injury. Kidney Int. Suppl. 2(1), 1\u2013138 (2012).","journal-title":"Kidney Int. Suppl."},{"issue":"3","key":"5867_CR2","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/cc11403","volume":"16","author":"S Morabito","year":"2012","unstructured":"Morabito, S. et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: A continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit. Care. 16(3), R111 (2012).","journal-title":"Crit. Care."},{"issue":"16","key":"5867_CR3","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2020.18618","volume":"324","author":"A Zarbock","year":"2020","unstructured":"Zarbock, A. et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: A randomized clinical trial. JAMA 324(16), 1629\u20131639 (2020).","journal-title":"JAMA"},{"issue":"2","key":"5867_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","volume":"30","author":"M Monchi","year":"2004","unstructured":"Monchi, M. et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 30(2), 260\u2013265 (2004).","journal-title":"Intensive Care Med."},{"issue":"6","key":"5867_CR5","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/j.1523-1755.2005.00342.x","volume":"67","author":"DJ Kutsogiannis","year":"2005","unstructured":"Kutsogiannis, D. J., Gibney, R. T., Stollery, D. & Gao, J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 67(6), 2361\u20132367 (2005).","journal-title":"Kidney Int."},{"issue":"5","key":"5867_CR6","first-page":"602","volume":"20","author":"MG Betjes","year":"2007","unstructured":"Betjes, M. G., van Oosterom, D., van Agteren, M. & van de Wetering, J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: Similar hemofilter survival but significantly less bleeding. J. Nephrol. 20(5), 602\u2013608 (2007).","journal-title":"J. Nephrol."},{"issue":"6","key":"5867_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/cc11645","volume":"16","author":"HM Oudemans-van Straaten","year":"2012","unstructured":"Oudemans-van Straaten, H. M. & Ostermann, M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit Care. 16(6), 249 (2012).","journal-title":"Crit Care."},{"issue":"2","key":"5867_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000342378","volume":"34","author":"A Tolwani","year":"2012","unstructured":"Tolwani, A. & Wille, K. M. Advances in continuous renal replacement therapy: Citrate anticoagulation update. Blood Purif. 34(2), 88\u201393 (2012).","journal-title":"Blood Purif."},{"issue":"4","key":"5867_CR9","first-page":"123","volume":"109","author":"R Apsner","year":"1997","unstructured":"Apsner, R. et al. Impairment of citrate metabolism in acute hepatic failure. Wien Klin Wochenschr. 109(4), 123\u2013127 (1997).","journal-title":"Wien Klin Wochenschr."},{"issue":"6","key":"5867_CR10","first-page":"439","volume":"2","author":"A Davenport","year":"2009","unstructured":"Davenport, A. & Tolwani, A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus 2(6), 439\u2013447 (2009).","journal-title":"NDT Plus"},{"issue":"3","key":"5867_CR11","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/cc11363","volume":"16","author":"A Link","year":"2012","unstructured":"Link, A. et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit. Care. 16(3), R97 (2012).","journal-title":"Crit. Care."},{"issue":"4","key":"5867_CR12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00003246-200104000-00010","volume":"29","author":"HU Meier-Kriesche","year":"2001","unstructured":"Meier-Kriesche, H. U., Gitomer, J., Finkel, K. & DuBose, T. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit. Care Med. 29(4), 748\u2013752 (2001).","journal-title":"Crit. Care Med."},{"issue":"6","key":"5867_CR13","doi-asserted-by":"publisher","first-page":"e65992","DOI":"10.1371\/journal.pone.0065992","volume":"8","author":"Y Zheng","year":"2013","unstructured":"Zheng, Y. et al. Citrate pharmacokinetics in critically ill patients with acute kidney injury. PLoS ONE 8(6), e65992 (2013).","journal-title":"PLoS ONE"},{"issue":"10","key":"5867_CR14","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1097\/01.CCM.0000084871.76568.E6","volume":"31","author":"L Kramer","year":"2003","unstructured":"Kramer, L. et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit. Care Med. 31(10), 2450\u20132455 (2003).","journal-title":"Crit. Care Med."},{"issue":"4","key":"5867_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s12072-019-09946-3","volume":"13","author":"SK Sarin","year":"2019","unstructured":"Sarin, S. K. et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update [published correction appears in Hepatol Int. 2019 Nov;13(6):826\u2013828]. Hepatol. Int. 13(4), 353\u2013390 (2019).","journal-title":"Hepatol. Int."},{"issue":"4","key":"5867_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.cld.2018.06.009","volume":"22","author":"JE Squires","year":"2018","unstructured":"Squires, J. E., McKiernan, P. & Squires, R. H. Acute liver failure: An update. Clin. Liver Dis. 22(4), 773\u2013805 (2018).","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"5867_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang, W. et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit. Care. 23(1), 22 (2019).","journal-title":"Crit. Care."},{"key":"5867_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea, F. et al. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin. Pharmacokinet. 46, 997\u20131038 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"5867_CR19","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1128\/AAC.00335-13","volume":"57","author":"S Weiler","year":"2013","unstructured":"Weiler, S. et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob. Agents Chemother. 57, 4053\u20134057 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"5867_CR20","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/jac\/dkz556","volume":"75","author":"R Welte","year":"2020","unstructured":"Welte, R. et al. Pharmacokinetics of trimethoprim\/sulfametrole in critically ill patients on continuous renal replacement therapy. J. Antimicrob. Chemother. 75(5), 1237\u20131241 (2020).","journal-title":"J. Antimicrob. Chemother."},{"issue":"6","key":"5867_CR21","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/jac\/dky057","volume":"73","author":"MG Sinnollareddy","year":"2018","unstructured":"Sinnollareddy, M. G. et al. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J. Antimicrob. Chemother. 73(6), 1647\u20131650 (2018).","journal-title":"J. Antimicrob. Chemother."},{"issue":"10","key":"5867_CR22","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1177\/03913988211021101","volume":"44","author":"C K\u00f6nig","year":"2021","unstructured":"K\u00f6nig, C. et al. Pharmacokinetics of meropenem during advanced organ support (ADVOS\u00ae) and continuous renal replacement therapy. Int. J. Artif. Organs 44(10), 783\u2013786 (2021).","journal-title":"Int. J. Artif. Organs"},{"issue":"10","key":"5867_CR23","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00467-002-0963-6","volume":"17","author":"V Chadha","year":"2002","unstructured":"Chadha, V., Garg, U., Warady, B. A. & Alon, U. S. Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr. Nephrol. 17(10), 819\u2013824 (2002).","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"5867_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/cc11645","volume":"16","author":"HM Oudemans-van Straaten","year":"2012","unstructured":"Oudemans-van Straaten, H. M. & Ostermann, M. Bench-to-bedside review: Citrate for continuous renal replacement therapy, from science to practice. Crit. Care 16(6), 249 (2012).","journal-title":"Crit. Care"},{"issue":"6","key":"5867_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MCC.0b013e3282f0a3d3","volume":"13","author":"M Schetz","year":"2007","unstructured":"Schetz, M. Drug dosing in continuous renal replacement therapy: General rules. Curr. Opin. Crit. Care 13(6), 645\u2013651 (2007).","journal-title":"Curr. Opin. Crit. Care"},{"issue":"6","key":"5867_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/sdi.12972","volume":"34","author":"SM Jang","year":"2021","unstructured":"Jang, S. M. & Awdishu, L. Drug dosing considerations in continuous renal replacement therapy. Semin. Dial. 34(6), 480\u2013488 (2021).","journal-title":"Semin. Dial."},{"issue":"1\u20133","key":"5867_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000440972","volume":"41","author":"M Zakharchenko","year":"2016","unstructured":"Zakharchenko, M. et al. Ionized magnesium and regional citrate anticoagulation for continuous renal replacement therapy. Blood Purif. 41(1\u20133), 41\u201347 (2016).","journal-title":"Blood Purif."},{"issue":"3","key":"5867_CR28","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CNQ.0000000000000118","volume":"39","author":"R Wonnacott","year":"2016","unstructured":"Wonnacott, R., Josephs, B. & Jamieson, J. CRRT regional anticoagulation using citrate in the liver failure and liver transplant population. Crit. Care Nurs. Q. 39(3), 241\u2013251 (2016).","journal-title":"Crit. Care Nurs. Q."},{"issue":"4","key":"5867_CR29","doi-asserted-by":"publisher","first-page":"R162","DOI":"10.1186\/cc11485","volume":"16","author":"C Schulthei\u00df","year":"2012","unstructured":"Schulthei\u00df, C. et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: A prospective observational study. Crit. Care. 16(4), R162 (2012).","journal-title":"Crit. Care."},{"issue":"5","key":"5867_CR30","doi-asserted-by":"publisher","first-page":"e0232516","DOI":"10.1371\/journal.pone.0232516","volume":"15","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Regional citrate anticoagulation versus no-anticoagulation for continuous venovenous hemofiltration in patients with liver failure and increased bleeding risk: A retrospective case-control study. PLoS ONE 15(5), e0232516 (2020).","journal-title":"PLoS ONE"},{"issue":"3","key":"5867_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ccell.2010.04.006","volume":"22","author":"S Lin","year":"2010","unstructured":"Lin, S. & Smith, B. S. Drug dosing considerations for the critically ill patient with liver disease. Crit. Care Nurs. Clin. North Am. 22(3), 335\u2013340 (2010).","journal-title":"Crit. Care Nurs. Clin. North Am."},{"issue":"22","key":"5867_CR32","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1056\/NEJMra1914900","volume":"382","author":"V Arroyo","year":"2020","unstructured":"Arroyo, V., Moreau, R. & Jalan, R. Acute-on-chronic liver failure. N. Engl. J. Med. 382(22), 2137\u20132145 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"5867_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.ajkd.2021.01.017","volume":"78","author":"H Rhee","year":"2021","unstructured":"Rhee, H., Berenger, B., Mehta, R. L. & Macedo, E. Regional citrate anticoagulation for continuous kidney replacement therapy with calcium-containing solutions: A cohort study. Am. J. Kidney Dis. 78(4), 550-559.e1 (2021).","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"5867_CR34","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/cc12756","volume":"17","author":"T Steele","year":"2013","unstructured":"Steele, T., Kolamunnage-Dona, R., Downey, C., Toh, C. H. & Welters, I. Assessment and clinical course of hypocalcemia in critical illness. Crit Care. 17(3), R106. https:\/\/doi.org\/10.1186\/cc12756 (2013).","journal-title":"Crit Care."},{"issue":"3","key":"5867_CR35","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1001\/archsurg.1992.01420030027005","volume":"127","author":"KW Burchard","year":"1992","unstructured":"Burchard, K. W., Simms, H. H., Robinson, A., DiAmico, R. & Gann, D. S. Hypocalcemia during sepsis: Relationship to resuscitation and hemodynamics. Arch. Surg. 127(3), 265\u2013272 (1992).","journal-title":"Arch. Surg."},{"issue":"5","key":"5867_CR36","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jhep.2016.12.003","volume":"66","author":"J Wendon","year":"2017","unstructured":"European Association for the Study of the Liver, Clinical Practice Guidelines Panel et al. EASL clinical practical guidelines on the management of acute (fulminant) liver failure. J. Hepatol. 66(5), 1047\u20131081 (2017).","journal-title":"J. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05867-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05867-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:55:21Z","timestamp":1669326921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05867-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5867"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05867-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"23 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1815"}}